Oncodesign Confirms Its Very Good Results in 2021 and an Att

Group turnover up by 23% at €31.3 millionOperating income and revenue of €36.2M, offsetting the foreseen discontinuation of the GSK subsidy (€8M)R&D investments amounting to €7.4MNet profit/loss near the break-even point (-€0.3M)Service BU:Very strong organic growth in external turnover at +31%, reaching €27.6M,EBIT...

Related Keywords

United States , Saclay , France General , France , Canada , Paris , French , American , Arnaud Lafforgue , Mathilde Bohin , Les Ulis , Philippe Genne , University Hospital , Investments In Research , Research Tax Credit , Oncodesign Group , Business Development , Regulatory News , Business Units , Artificial Intelligence , Chief Financial Officer , North American , Drug Discovery , Statutory Auditor , Euronext Growth Market ,